May 10, 2024 8:17am

Earnings and economic data releases alongside market rejoinders usually send equities seesawing back and forth

Earnings: Prime Medicine (PRME)

Pre-open Indications: 4 Positive and 1 Negative Indications

I am right more often than not and investors have always been able to count on … RMi for return on investment (ROI); start thinking return on speculation

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RM

 

Friday: The pre-open Dow futures are UP +0.20% or (+80 points), the S&P futures are UP +0.29% or (+15 points) as the Nasdaq futures are +0.37% or (+66 points)

U.S. stock futures rose Friday

European markets were higher,

Asia-Pacific markets were also higher.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday: The Dow closed UP +331.37 points or +0.85%, the S&P closed UP +26.41points or +0.51% while the Nasdaq closed UP +43.51 points or +0.27%

Economic Data Docket: U. Michigan Consumer Index

  • Expected to ease slightly to 76.0, down from 77.2.

 

Thursday night’s RegMed Investors (RMi) Closing Bell: “elasticity. The ability of share pricing to resume an improved valuation after being stretched or compressed.” …  https://www.regmedinvestors.com/articles/13454

 

Q2/24:  May – 5 positive and 2 negative closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Negative indications:

Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Intellia Therapeutics (NTLA) closed up +$1.86 after Wednesday’s -$0.88, Tuesday’s +$0.16 and Monday’s +$0.12 with a negative -$0.36 or -1.45% pre-open indication

 

Positive indications:

Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Agenus (AGEN) closed up +$0.25 after Wednesday’s -$0.54, Tuesday’s -$0.94 and Monday’s -$0.12 with a positive +$0.45 or +3.84% pre-open indication.

Beam Therapeutics (BEAM) closed up +$0.30 with a positive +$0.14 or +0.62% pre-open indication.

CRISPR Therapeutics (CRSP) closed up +$0.26 after Wednesday’s -$2.24, Tuesday’s -$1.53 and Monday’s +$1.17 with a positive +$0.67 or +1.25% pre-open indication.

Vericel (VCEL) closed up +$0.96 after Wednesday’s -$1.83, Tuesday’s +$2.58 and Monday’s -$0.89 with a neutral pre-open indication.

 

The BOTTOM LINE: a bounce of the oversold could become an overbought exercise – it’s coming.

Adding earnings post Thursday’s close: https://www.regmedinvestors.com/articles/11628

  • BioLife Solutions (BLFS) net loss of -$10.2 M or -$0.22 per share, revenue: $31.7 M, cash position = $46.1 M and a runway until 2026
  • Fate Therapeutics (FATE) net loss of $48 M or -$0.47 per share, revenue: $1.93 M, cash position = $391.1 M and a runway until 2025
  • Sangamo therapeutics (SGMO) net loss of $49.1 M or -$0.27 per share, revenue: $480 K, cash position = $54.4 M and a runway until Q3/24
  • Adverum Biotechnologies (ADVM) net loss of $24.8 M or -$1.50 per share, revenue: $0 , cash position = $193.3 M and a runway until Q3-4/25

Coming date: https://www.regmedinvestors.com/articles/13441

  • Precigen (PGEN) Tuesday, 5/14

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.